Ambeed.cn

首页 / 抑制剂/激动剂 / 神经信号通路 / NK Receptor / SB-222200

SB-222200 {[allProObj[0].p_purity_real_show]}

货号:A875802

SB-222200是一种选择性、可逆且竞争性的人的NK-3受体拮抗剂(Ki=4.4 nM),能够有效穿透血脑屏障。

SB-222200 化学结构 CAS号:174635-69-9
SB-222200 化学结构
CAS号:174635-69-9
SB-222200 3D分子结构
CAS号:174635-69-9
SB-222200 化学结构 CAS号:174635-69-9
SB-222200 3D分子结构 CAS号:174635-69-9
规格 价格 会员价 库存 数量
{[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

SB-222200 纯度/质量文件 产品仅供科研

货号:A875802 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
Cell, 2025, 188, (21): 5847-5861.e11. Ambeed. [ A122167 ]
Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
Nat. Nanotechnol., 2025, 20, 1502-1513. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

SB-222200 生物活性

描述 NK-3 receptors are G-protein coupled receptors activated by mammalian tachykinins, which can modulate dopaminergic neurotransmission, and thus may play a role in development and expression of behavioral sensitization[3]. SB-222200 is a human NK-3 receptor (hNK-3R) antagonist. SB-222200 inhibited 125I-[MePhe7] neurokinin B (NKB) binding to Chinese hamster ovary (CHO) cell membranes stably expressing the hNK-3 receptor with a Ki of 4.4 nM and antagonized NKB-induced Ca2+ mobilization in HEK 293 cells stably expressing the hNK-3 receptor with an IC50 of 18.4 nM. SB-222200 was selective for hNK-3 receptors compared with hNK-1 (Ki > 100,000 nM) and hNK-2 receptors (Ki = 250 nM). In HEK 293 cells transiently expressing murine NK-3 receptors, SB-222200 inhibited binding of 125I-[MePhe7]NKB (Ki = 174 nM) and antagonized NKB (1 nM)-induced calcium mobilization (IC50 = 265 nM). In mice oral administration of SB-222200 produced dose-dependent inhibition of behavioral responses induced by i.p. or intracerebral ventricular administration of the NK-3 receptor-selective agonist, senktide, with ED50 value of approximately 5 mg/kg. Pharmacokinetic evaluation of SB-222200 in rat after oral administration (8 mg/kg) indicated sustained plasma concentrations (Cmax) = 400 ng/mL) and bioavailability of 46% [2]. Administration of SB-222200 (5 mg/kg, s.c.) prior to repeated cocaine (20 mg/kg, i.p.) prevented the development of sensitized responses after a cocaine challenge.

SB-222200 细胞实验

Cell Line
Concentration Treated Time Description References
Bone marrow-derived macrophages (BMDMs) 10 µM 1 hour SB-222200 inhibits the activation of the NLRP3 inflammasome, reducing IL-1β release. Cell Mol Life Sci. 2023 Jul 27;80(8):230
J774A.1 cells 10 µM 1 hour SB-222200 effectively inhibits the activation of the NLRP3 inflammasome, reducing IL-1β release. Cell Mol Life Sci. 2023 Jul 27;80(8):230
COS-7 cells 0.001–1000 µM 10 minutes To study the antagonistic effect of SB-222200 on tiTac3Ra, results showed that SB-222200 had a strong inhibitory effect on tiTac3Ra with IC50 values of 84.11 μM (tiNKB) and 37.05 μM (tiNKF). Biology (Basel). 2021 Sep 27;10(10):968
Rabbit iris sphincter muscle 0.3-3 µM 120 minutes To evaluate the antagonistic effect of SB-222200 on [MePhe7]-NKB-induced contraction. Results showed that SB-222200 inhibited responses to low concentrations (<1 nM) of [MePhe7]-NKB to a greater extent than responses to higher concentrations (>1 nM) of [MePhe7]-NKB, and made the concentration-effect curves steeper and monophasic. Br J Pharmacol. 1997 Oct;122(3):469-76
Rabbit iris sphincter muscle 30-300 nM 120 minutes To evaluate the antagonistic effect of SB-222200 on senktide-induced contraction. Results showed that SB-222200 antagonized senktide-induced contraction in a surmountable and concentration-dependent manner, with a pA2 value of 7.89. Br J Pharmacol. 1997 Oct;122(3):469-76
Human airway smooth muscle cells (HASM) 100 µM 30 minutes SB-222200, as a selective NK3R antagonist, significantly inhibited senktide-induced inositol phosphate synthesis and intracellular Ca2+ concentration increase. Am J Physiol Lung Cell Mol Physiol. 2008 Mar;294(3):L523-34

SB-222200 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
New Zealand White rabbits Conscious rabbits Intravenous injection 1 and 2 mg/kg Single administration, observed for 30 minutes To evaluate the inhibitory effect of SB-222200 on senktide-induced pupillary constriction. Results showed that SB-222200 significantly inhibited senktide-induced pupillary constriction, with a maximum inhibition of 100%. Br J Pharmacol. 1997 Oct;122(3):469-76
C57BL/6 mice MSU-induced peritonitis Intraperitoneal injection 10, 15, 20 mg/kg Single dose SB-222200 dose-dependently reduced the production of IL-1β and IL-6 in the peritoneal fluid, alleviating MSU-induced peritonitis. Cell Mol Life Sci. 2023 Jul 27;80(8):230
Nile tilapia (Oreochromis niloticus) Adult male tilapia Intraperitoneal injection 100 μg/kg Single injection, observed for 2 hours To study the effect of SB-222200 on LH and FSH release, results showed that SB-222200 significantly reduced LH plasma levels but had no significant effect on FSH levels. Biology (Basel). 2021 Sep 27;10(10):968
CD-1 mice Cocaine-induced hyperactivity model Subcutaneous injection 2.5 or 5 mg/kg Single dose or once daily for 5 days To investigate the effects of SB 222200 on cocaine-induced hyperactivity. Results showed that acute administration of SB 222200 attenuated cocaine-induced stereotypic behavior, while repeated administration enhanced hyperactivity induced by cocaine or a low dose of SKF 82958. Neuropharmacology. 2009 Sep;57(3):295-301
Caenorhabditis elegans Wild-type and mutants Culture medium administration 200 nM Single dose, duration not specified SB222200, a high-affinity human tachykinin receptor antagonist, increased the pharyngeal pumping rate in C. elegans PLoS Biol. 2013 Nov;11(11):e1001712
Female C57Bl6/J mice Ovariectomized (OVX) mice Bilateral intra-MePD administration 4.20 pmol (initial dose) and 8.30 pmol (continuous dose) Initial dose for 5 minutes, continuous dose for 65 minutes To investigate whether SB222200 in the MePD can block the suppressive effect of predator odor (TMT) on LH pulsatility. Results showed that SB222200 completely blocked TMT-induced suppression of LH pulses. J Neuroendocrinol. 2024 May;36(5):e13384
Mice NK1 receptor knockout mice Intravenous injection 5 mg/kg Single dose, experiments conducted 15 minutes after administration To evaluate the effect of SB-222200 on NKB-induced plasma extravasation in the lung, results showed that SB-222200 had no significant effect on NKB-induced plasma extravasation. J Physiol. 2002 Sep 15;543(Pt 3):1007-14
Adult male CD-1 mice Cocaine-induced behavioral sensitization model Subcutaneous injection 5 mg/kg Once daily for 5 days Pretreatment with SB 222200 prevented the development of cocaine-induced behavioral sensitization and blocked the expression of sensitization when administered prior to a cocaine challenge. Additionally, SB 222200 reversed tolerance to increased GSK3 phosphorylation following repeated cocaine administration. J Neurochem. 2010 Nov;115(3):635-42
Spontaneously hypertensive rats (SHR) Spontaneously hypertensive rat model Intracerebroventricular (i.c.v.) or ventral tegmental area (VTA) injection 500 pmol Single injection, effect lasted for 8-10 hours To investigate the antihypertensive effect of SB222200 in spontaneously hypertensive rats and its mechanism. Results showed that SB222200 produced antihypertensive effects via activation of dopamine D2 receptors in the ventral tegmental area. Br J Pharmacol. 2010 Dec;161(8):1868-84
Mice Pregnancy-induced hypertension and proteinuria model Intravenous injection 75 μg/mL Once on gestational day 13 and day 14 SB222200 treatment significantly reduced mean systolic pressure and proteinuria in CRP-infused pregnant mice, improved glomerular and placental damage, and decreased sFlt-1 levels Hypertension. 2015 Feb;65(2):430-9

SB-222200 参考文献

[1]King AG, Sanger GJ. Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret. Neurosci Lett. 2005 Mar 7;376(1):5-8.

[2]Sarau HM, Griswold DE, Bush B, et al. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist. J Pharmacol Exp Ther. 2000;295(1):373-381.

[3]Nwaneshiudu CA, Unterwald EM. NK-3 receptor antagonism prevents behavioral sensitization to cocaine: a role of glycogen synthase kinase-3 in the nucleus accumbens. J Neurochem. 2010;115(3):635-642.

SB-222200 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.63mL

0.53mL

0.26mL

13.14mL

2.63mL

1.31mL

26.28mL

5.26mL

2.63mL

SB-222200 技术信息

CAS号174635-69-9
分子式C26H24N2O
分子量 380.48
SMILES Code O=C(C1=C(C)C(C2=CC=CC=C2)=NC3=CC=CC=C13)N[C@H](C4=CC=CC=C4)CC
MDL No. MFCD00944072
别名
运输蓝冰
InChI Key MQNYRKWJSMQECI-QFIPXVFZSA-N
Pubchem ID 6604009
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Sealed in dry, 2-8°C

溶解方案

DMSO: 105 mg/mL(275.97 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂:
——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
方案 一
方案 二
AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。